Pirtobrutinib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 203 publications

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.

Journal: Annals of hematology
Published: August 20, 2026

Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review.

Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review.

Journal: American journal of clinical oncology
Published: August 13, 2026

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 07, 2026

Recent advances and future perspectives in the treatment of chronic lymphocytic leukemia

Recent advances and future perspectives in the treatment of chronic lymphocytic leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 03, 2026

Recurrent Granulomatous Panuveitis and Sarcoidosis-Like Reaction Associated with Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Recurrence After Switching from Ibrutinib to Pirtobrutinib.

Recurrent Granulomatous Panuveitis and Sarcoidosis-Like Reaction Associated with Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Recurrence After Switching from Ibrutinib to Pirtobrutinib.

Journal: Ocular immunology and inflammation
Published: July 16, 2026

Sonrotoclax (Beqalzi) for mantle cell lymphoma.

Sonrotoclax (Beqalzi) for mantle cell lymphoma.

Journal: The Medical letter on drugs and therapeutics
Published: July 14, 2026

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.

Journal: Cancers
Published: July 08, 2026

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Journal: Leukemia & lymphoma
Published: June 21, 2026

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

Journal: Expert opinion on drug discovery
Published: June 15, 2026

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

Journal: Expert opinion on pharmacotherapy
Published: May 29, 2026

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy.

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy.

Journal: British journal of haematology
Published: May 15, 2026

Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data.

Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data.

Journal: Hematology reports
Published: May 13, 2026
Showing 1-12 of 203

Last Updated: 09/26/2026